I last covered Moderna, Inc. (NASDAQ:MRNA), shortly after the Cambridge, Massachusetts-based messenger-RNA specialist reported its Q2 earnings. I gave its stock a Buy rating, with shares price at $27.6, and today they are
Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis.
This news is powered by Seeking Alpha 
